"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Those two programs are unlikely to be big earners. But assuming they get approved, they'll help to prove that in principle, Moderna's platform is capable of developing innovative solutions to ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Where Summit Therapeutics ( SMMT -7.92%) falls on that spectrum is a big question mark right now. It has been among the hottest healthcare stocks to own over the past 12 months, as its valuation has ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...